In 2021, Autolus signed a strategic collaboration with Blackstone, where Blackstone committed to invest up to $250 million to develop obe-cel in adult ALL. This collaboration validates the commercial opportunity in adult ALL and funds development and filing of obe-cel in relapsed / refractory adult ALL, as well as funding commercial and manufacturing infrastructure build.
In 2021, Autolus and Moderna signed an option and license agreement for access to proprietary targeting technology from Autolus. The agreement granted exclusive access to develop and commercialize mRNA therapeutics for up to four immuno-oncology targets.
We have been collaborating with UCL since Autolus was founded. Our strategic collaboration leverages expertise from clinical and translation sciences teams across the two organizations and allows us to rapidly develop programs into the clinic. Our partnership with UCL has been critical to demonstrating the clinical benefits of obe-cel in patients with adult ALL.